Accretion Pharmaceuticals Ltd

Accretion Pharmaceuticals Investor Presentation: Key Takeaways

H1 FY27 revenue ₹55.04 Cr (+25.83% YoY), PAT ₹8.20 Cr (+72.63%), EBITDA margin 22.48%. Export share rose to 18.15%.

Accretion Pharmaceuticals Results Update

Accretion Pharmaceuticals reported H1 FY27 net revenue up 25.83% to ₹55.04 crore and PAT up 72.63% to ₹8.20 crore via media release. EBITDA margin improved to 22.48%.

Accretion Pharmaceuticals H1 FY27 Results: Net Profit ₹8.2 Cr, Up 70.8% YoY

Accretion Pharmaceuticals reported unaudited standalone half-year results to 30 September 2026, with revenue of Rs 5,504.10 lakh and profit after tax of Rs 820.14 lakh. The results carry a limited review report from VSSB & Associates.

Key figure

Net profit ₹8.2 Cr · +70.8% YoY

Accretion Pharmaceuticals Annual General Meeting

Accretion Pharmaceuticals Limited announced the results of its postal ballot, where shareholders approved five special resolutions, including increasing borrowing limits and charging company assets.

Accretion Pharmaceuticals Other Announcement

Accretion Pharmaceuticals Limited submitted the confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.

Accretion Pharmaceuticals Annual General Meeting

Accretion Pharmaceuticals Limited issued a postal ballot notice to shareholders to seek approval for altering the company's Memorandum of Association (Object Clause).

Accretion Pharmaceuticals Other Announcement

Accretion Pharmaceuticals Limited approved an alteration to its Memorandum of Association to expand its business objects. The Board also approved increased borrowing and investment limits subject to shareholder approval.

Accretion Pharmaceuticals Annual General Meeting

Accretion Pharmaceuticals Limited held its 3rd Annual General Meeting on August 27, 2026. The meeting transacted business including the adoption of financial statements and director re-appointment.

Accretion Pharmaceuticals Other Announcement

Accretion Pharmaceuticals Limited has provided the web link for shareholders to access its Annual Report for FY 2025-26 and the 3rd AGM notice.

Accretion Pharmaceuticals Annual General Meeting

Accretion Pharmaceuticals Limited has scheduled its 3rd Annual General Meeting for August 27, 2026, to be conducted through video conferencing for ordinary business transactions.

Accretion Pharmaceuticals Management Change

Accretion Pharmaceuticals' HR Manager, Ms. Bandana Kumari, resigned effective 2nd July 2026. The resignation is for personal reasons, with no material issues reported.

Accretion Pharmaceuticals Results Correction

Accretion Pharmaceuticals responded to exchange clarifications regarding financial results. The company provided an auditor's certificate confirming ₹27.75 Crore in IPO fund utilization.

Value

₹27.75 Cr

Accretion Pharmaceuticals Earnings Call: Key Takeaways

Accretion Pharmaceuticals reported strong FY26 performance with ₹89.63 cr total income and 10.8% PAT margin, driven by export growth.

Accretion Pharmaceuticals Board Meeting Outcome

Accretion Pharmaceuticals approved the appointment of a new HR Manager and internal/secretarial auditors. These appointments strengthen the company's leadership and regulatory compliance frameworks.

Execution

12 months

Accretion Pharmaceuticals H2 FY26 Results: Net Profit ₹4.9 Cr, Up 14.0% YoY

Accretion Pharmaceuticals Ltd reported revenue from operations of ₹45.9 Cr (+18.3% YoY) and net profit of ₹4.9 Cr (+14.0% YoY) for H2 FY26.

Key figure

Net profit ₹4.9 Cr · +14.0% YoY

Accretion Pharmaceuticals Financial Results

Accretion Pharmaceuticals approved its FY26 audited financial results and appointed Ms. Bandana Kumari as HR Manager. Net profit for the period reached ₹9.67 Crore.

Accretion Pharmaceuticals Other Announcement

Accretion Pharmaceuticals Limited submitted its annual Structured Digital Database (SDD) compliance certificate for the financial year ended March 31, 2026. The certificate, issued by M/s. Sakhiya & Co., confirms that the company maintains a non-tamperable digital database for tracking UPSI events in accordance with SEBI Insider Trading Regulations.

Accretion Pharmaceuticals Board Meeting Date

Accretion Pharmaceuticals Limited has scheduled a Board Meeting for May 8, 2026, to consider and approve its audited standalone financial results for the year ended March 31, 2026. Consequently, the trading window for designated persons has been closed from April 1, 2026.

Accretion Pharmaceuticals Other Announcement

Accretion Pharmaceuticals Limited informed the National Stock Exchange that it does not fall under the 'Large Corporate' category for the financial year 2026–2027. Consequently, the specific disclosure and compliance requirements for debt security issuance by large entities under SEBI circulars are not applicable to the company.

Accretion Pharmaceuticals Other Announcement

Accretion Pharmaceuticals Limited informed the NSE that Regulation 27(2) regarding quarterly corporate governance reports is not applicable. As an SME-listed entity, the company is exempt under SEBI LODR Regulation 15(2)(b). A certificate from Sakhiya & Co confirms this non-applicability for the quarter ended March 31, 2026.

Accretion Pharmaceuticals Other Announcement

Accretion Pharmaceuticals Limited submitted its Regulation 74(5) compliance certificate for the quarter ended March 31, 2026. The certificate from RTA KFin Technologies confirms that all company shares are in dematerialized form and no rematerialization requests were received during the period.